Filing summary
Entity and period: The request identifies BONK, INC., but the supplied filing is Jupiter Wellness, Inc. (Nasdaq: JUPW; warrants: JUPWW), Form 10-Q for the quarter ended September 30, 2021. The summary below reflects the supplied filing; verify the intended issuer before relying on it.
Business context
Jupiter Wellness develops CBD-based medical therapeutics and wellness products, including consumer skin and sun-care products, and has a clinical pipeline of topical treatments. It also owns SRM Entertainment, a supplier to amusement parks and entertainment venues. The filing covers the three and nine months ended September 30, 2021, compared with the same 2020 periods.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $687,928 | $178,335 | $1,331,862 | $753,729 |
| Gross profit | $2,159 | $81,727 | $208,728 | $320,424 |
| Gross margin | 0.3% | 45.8% | 15.7% | 42.5% |
| Net loss | $4,808,430 | $607,289 | $11,155,267 | $1,522,462 |
| Basic loss per share | $0.24 | $0.09 | $0.79 | $0.22 |
For the nine months, operating cash use was $5.0 million; investing cash use was $0.5 million; financing provided $28.1 million; and cash increased by $22.6 million to $26.9 million. At September 30, cash was $26.9 million, working capital was $27.3 million, total assets were $31.4 million, and total liabilities were $1.8 million. Convertible notes had been repaid or converted, leaving none outstanding. Liabilities included $84,354 under SBA programs and $842,515 of lease liabilities.
Changes and significant items
- Nine-month revenue rose 77% year over year, but gross profit declined 35%; cost of sales rose faster than revenue. In Q3, gross profit was nearly zero despite higher sales.
- Net loss widened substantially. General and administrative expense was $10.3 million for the nine months; stock-based compensation was $5.5 million, and interest expense was $1.7 million, including substantial noncash discount and warrant-related charges.
- A July public offering raised $28.3 million net through issuance of 11.1 million common shares and warrants. At quarter-end, 13.7 million warrants were outstanding, all exercisable; the filing also reports 1.4 million options outstanding.
- The company recognized a $669,200 gain from settlement and forgiveness of a note related to its Magical Beasts acquisition. It also acquired rights to patented technologies for $675,000, paid partly in stock.
- Research and development expense rose to $917,714 for the nine months, from $98,619 in 2020.
Outlook, risks, and contingencies
No quantified revenue or earnings guidance is provided. Management said it expects continued significant costs for expansion and development and believes offering proceeds provide sufficient capital to execute its business plan. The filing nevertheless describes the company’s accumulated deficit and operating cash burn as having raised going-concern doubt; management says the financing alleviated the need for a going-concern opinion.
Management cited weakened demand for traditional products related to COVID-19. Product development, stability testing, clinical trials, and any FDA approvals remain uncertain; the filing describes the business as early-stage. A pending federal lawsuit includes the company’s claims for $5 million actual and $5 million punitive damages, while certain breach-of-contract and unjust-enrichment counterclaims remain. The company also loaned $293,300 to an affiliate connected to a proposed SPAC and disclosed a potential $2.05 million funding obligation if its offering succeeds. A new five-year office lease began in July 2021.
Management reported disclosure controls effective as of September 30, 2021 and described remediation of prior internal-control weaknesses involving segregation of duties and control documentation. The company is an emerging growth company and uses the extended transition period for new accounting standards.
Investor verification points
- Confirm that Jupiter Wellness, Inc. (JUPW), rather than BONK, INC., is the intended issuer and filing.
- Reconcile the filing’s reported Q3 net loss: the statements and MD&A report $4,808,430, while a note’s loss-per-share table lists $4,848,430.
- Assess whether the near-zero Q3 gross margin and continuing operating cash burn are sustainable, and how quickly the $26.9 million cash balance may be used.
- Review the potential dilution from outstanding warrants and options, including the terms and count of the 2021 offering warrants.
- Verify the status, terms, and funding exposure of the affiliate loan and proposed SPAC transaction, as well as the remaining litigation claims and product regulatory milestones.